soho2023
ELEVENTH ANNUAL MEETING

FOLLICULAR LYMPHOMA: CONCENTRIC STUDY IN THE HEMATOLOGY DEPARTMENT OF THE IBN ROCHD UNIVERSITY HOSPITAL CENTER

H. MAATAOUI-BELABBES [1]. M. QACHOUH [1] . N.MOUFID [1]. A. BENMOUSSA [1]. M. LAMCHAHAB [1]. M.RACHID [1]. S. CHERKAOUI [1]. N. KHOUBILA. [1] A. MADANI [1].
1. Department of Hematology and Pediatric Oncology- Hospital August 20th1953- IBN ROCHD, Casablanca, Morocco

INTRODUCTION

Follicular lymphoma (FL) is a systemic neoplasm of the lymphoid tissue displaying germinal center B cell differentiation.
It represents 5% of all hematological neoplasms and 20-25%of all new non-Hodgkin lymphoma.

AIM


Determine the epidemiological, clinical, and paraclinical characteristics of Follicular Lymphoma in our population.


METHOD


Descriptive retrospective study carried out at the August 20th 1953 Hospital , Hematology Department in Casablanca.
From January 2018 to December 2022, 33 patients with newly diagnosticated Follicular Lymphoma.
We recorded epidemiological data, clinical, histological and therapeutic.
The scores used were Ann Arbor, GELF and FLIPI


RESULTS


STUDY RESULTS	
PATIENT NUMBER	33
AVERAGE AGE	54 [35-80]
SEXE RATIO M/F	1,2
PS	1 [0-3]
LDH	302 [133-698]
BETA2 MICROGLOBULIN	2,32
GELF SCORE ≥2	17
FLIPI INDEX ≥2	22











THERAPEUTIC PROTOCOL	NUMBER OF PATIENTS	COMPLETE REMISSION	PARTIAL REMISSION	FAILURE
RCHOP	25	23	1	1
RCHOP + HIGH MTX DOSE (for spinal cord compression)	1	1	-	-
RCVP	4	1	1	2
R MINI CHOP	3	1	1	1
WAIT AND SEE	2 (≈7 months)	-	-	-
CYTOREDUCTIVE COP	10	3 (Good response)	-	-
Rituximab maintenance for 2 years	5	-	-	-
SALVAGE THERAPY				
- R BGev	3	2	0	1
- R BAC	2	2	0	0
- R DHAOx	2	1	1	0
+ STEM CELL TRANSPLANT	2			
TIME TO RELAPSE	12 (1 autaugraft)	2.6 years [3 month- 4.5 years]		
-R DHAOx	4	3	0	1
-R Bgev	4	2	1	1
- R BAC	2	1	1	0
-Chlorambucil/prednisolone	1	1	0	0
-CVP	1	0	1	0
+ STEM CELL TRANSPLANT	5			

CONCLUSIONS

Outcomes for FL with R-CHOP are encouraging. Most of our patients have not received Rituximab maintenance for lack of means. Refractory and relapsed disease in autograft patients constitutes a therapeutic challenge.

REFERENCES

1. M Dreyling et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 32 (3), 298-308, 2021
2. Arnold Freedman, Eric Jacobsen. Follicular lymphoma: 2020 update on diagnosis and management. American Journal of Hematology 95 (3), 316-327, 2020